西格列汀二甲双胍治疗初诊断2型糖尿病的临床观察  

Clinical Observation on Sitagliptin Plus Metformin in Treatment of Patients Initially Diagnosed with Type 2 Diabetes

作　　者：周珈莉[1] 张建伟[1] ZHOU Jia-li;ZHANG Jian-wei(Department of endocrinology,Kunming First People’s Hospital,Kunming,Yunnan Province,650011 China)

机构地区：[1]昆明市第一人民医院内分泌科,云南昆明650011

出　　处：《糖尿病新世界》2018年第13期87-89,共3页Diabetes New World Magazine

摘　　要：目的观察用西格列汀二甲双胍片治疗初诊断2型糖尿病的有效性和安全性。方法将2015年1月—2016年10月收治的40例新诊断2型糖尿病患者按照HbA1c水平分为A、B两组,采用二肽基肽酶-4(DPP-4)西格列汀二甲双胍复方制剂(50 mg西格列汀/500 mg盐酸二甲双胍)治疗,持续治疗30周。结果治疗24周后,空腹血糖,餐后2 h血糖、BMI、胰岛素释放水平与治疗前比较差异有统计学意义(P<0.05),血脂、肝肾功与治疗前比较差异无统计学意义(P>0.05)。无低血糖事件,未发生其它不良反应。结论西格列汀二甲双胍治疗初诊断2型糖尿病患者,可有效降低HbA1c及4个时点血糖(空腹及三餐后2 h血糖)。Objective To observe the effectiveness and safety of sitagliptin plus metformin in treatment of patients initially diagnosed with type 2 diabetes.Methods 40 cases of patients with type 2 diabetes were divided into the group A and group from January 2015 to October 2016 according to the HbA1c level,treated with dipeptidyl peptidase-4(DPP-4)sitagliptin plus metformin compound preparation(50 mg sitagliptin/500 mg metformin hydrochloride),for 30 weeks in a row.Results After 24 weeks,the differences in the fasting blood glucose,postprandial 2 h blood glucose,BMI,insulin release level before and after treatment were statistically significant(P<0.05),and the differences in the blood liquid,liver and renal functions before and after treatment were not statistically significant(P>0.05),without the hypoglycemia events and other adverse reactions.Conclusion The sitagliptin plus metformin in treatment of patients initially diagnosed with type 2 diabetes can effectively reduce the HbA1c and blood glucose levels at four time points(fasting blood glucose and postprandial 2 h blood glucose).

关 键 词：初诊断2型糖尿病 西格列汀 二甲双胍片 HBA1C 

分 类 号：R59[医药卫生—内科学]